ID CPT1A_HUMAN Reviewed; 773 AA. AC P50416; Q8TCU0; Q9BWK0; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 07-DEC-2004, sequence version 2. DT 27-MAR-2024, entry version 212. DE RecName: Full=Carnitine O-palmitoyltransferase 1, liver isoform; DE Short=CPT1-L; DE EC=2.3.1.21 {ECO:0000269|PubMed:11350182, ECO:0000269|PubMed:9691089}; DE AltName: Full=Carnitine O-palmitoyltransferase I, liver isoform; DE Short=CPT I; DE Short=CPTI-L; DE AltName: Full=Carnitine palmitoyltransferase 1A; GN Name=CPT1A {ECO:0000312|HGNC:HGNC:2328}; Synonyms=CPT1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Liver; RX PubMed=7892212; DOI=10.1073/pnas.92.6.1984; RA Britton C.H., Schultz R.A., Zhang B., Esser V., Foster D.W., McGarry J.D.; RT "Human liver mitochondrial carnitine palmitoyltransferase I: RT characterization of its cDNA and chromosomal localization and partial RT analysis of the gene."; RL Proc. Natl. Acad. Sci. U.S.A. 92:1984-1988(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS CPT1AD VAL-414 AND CYS-498, AND RP VARIANT THR-275. RX PubMed=12189492; DOI=10.1007/s00439-002-0752-0; RA Gobin S., Bonnefont J.-P., Prip-Buus C., Mugnier C., Ferrec M., RA Demaugre F., Saudubray J.-M., Rostane H., Djouadi F., Wilcox W., RA Cederbaum S., Haas R., Nyhan W.L., Green A., Gray G., Girard J., RA Thuillier L.; RT "Organization of the human liver carnitine palmitoyltransferase 1 gene RT (CPT1A) and identification of novel mutations in hypoketotic RT hypoglycaemia."; RL Hum. Genet. 111:179-189(2002). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-473. RX PubMed=16651524; DOI=10.1073/pnas.0602205103; RA Wolfgang M.J., Kurama T., Dai Y., Suwa A., Asaumi M., Matsumoto S., RA Cha S.H., Shimokawa T., Lane M.D.; RT "The brain-specific carnitine palmitoyltransferase-1c regulates energy RT homeostasis."; RL Proc. Natl. Acad. Sci. U.S.A. 103:7282-7287(2006). RN [6] RP INDUCTION BY FATTY ACIDS. RX PubMed=16271724; DOI=10.1016/j.jmb.2005.09.097; RA Napal L., Marrero P.F., Haro D.; RT "An intronic peroxisome proliferator-activated receptor-binding sequence RT mediates fatty acid induction of the human carnitine palmitoyltransferase RT 1A."; RL J. Mol. Biol. 354:751-759(2005). RN [7] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [8] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [9] RP 3D-STRUCTURE MODELING. RX PubMed=14711372; DOI=10.1042/bj20031373; RA Morillas M., Lopez-Vinas E., Valencia A., Serra D., Gomez-Puertas P., RA Hegardt F.G., Asins G.; RT "Structural model of carnitine palmitoyltransferase I based on the RT carnitine acetyltransferase crystal."; RL Biochem. J. 379:777-784(2004). RN [10] RP STRUCTURE BY NMR OF 1-42, AND DOMAIN. RX PubMed=21990363; DOI=10.1074/jbc.m111.306951; RA Rao J.N., Warren G.Z., Estolt-Povedano S., Zammit V.A., Ulmer T.S.; RT "An environment-dependent structural switch underlies the regulation of RT carnitine palmitoyltransferase 1A."; RL J. Biol. Chem. 286:42545-42554(2011). RN [11] RP VARIANT CPT1AD GLY-454, CHARACTERIZATION OF VARIANT CPT1AD GLY-454, RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=9691089; DOI=10.1172/jci2927; RA Ijlst L., Mandel H., Oostheim W., Ruiter J.P.N., Gutman A., Wanders R.J.; RT "Molecular basis of hepatic carnitine palmitoyltransferase I deficiency."; RL J. Clin. Invest. 102:527-531(1998). RN [12] RP VARIANTS CPT1AD CYS-123; TRP-304; TRP-357; ARG-395 DEL; LEU-479 AND RP PRO-484, AND VARIANT THR-275. RX PubMed=11441142; RA Brown N.F., Mullur R.S., Subramanian I., Esser V., Bennett M.J., RA Saudubray J.-M., Feigenbaum A.S., Kobari J.A., Macleod P.M., McGarry J.D., RA Cohen J.C.; RT "Molecular characterization of L-CPT I deficiency in six patients: insights RT into function of the native enzyme."; RL J. Lipid Res. 42:1134-1142(2001). RN [13] RP VARIANT CPT1AD GLU-710, CHARACTERIZATION OF VARIANT CPT1AD GLU-710, RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL RP PROPERTIES. RX PubMed=11350182; DOI=10.1006/mgme.2001.3176; RA Prip-Buus C., Thuillier L., Abadi N., Prasad C., Dilling L., Klasing J., RA Demaugre F., Greenberg C.R., Haworth J.C., Droin V., Kadhom N., Gobin S., RA Kamoun P., Girard J., Bonnefont J.-P.; RT "Molecular and enzymatic characterization of a unique carnitine RT palmitoyltransferase 1A mutation in the Hutterite community."; RL Mol. Genet. Metab. 73:46-54(2001). RN [14] RP CHARACTERIZATION OF VARIANT CPT1AD GLY-360. RX PubMed=12111367; DOI=10.1007/s100380200047; RA Ogawa E., Kanazawa M., Yamamoto S., Ohtsuka S., Ogawa A., Ohtake A., RA Takayanagi M., Kohno Y.; RT "Expression analysis of two mutations in carnitine palmitoyltransferase IA RT deficiency."; RL J. Hum. Genet. 47:342-347(2002). RN [15] RP VARIANT CPT1AD GLU-709, CHARACTERIZATION OF VARIANTS CPT1AD THR-275; RP VAL-414; CYS-498; GLU-709 AND GLU-710, SUBCELLULAR LOCATION, FUNCTION, RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=14517221; DOI=10.1074/jbc.m310130200; RA Gobin S., Thuillier L., Jogl G., Faye A., Tong L., Chi M., Bonnefont J.-P., RA Girard J., Prip-Buus C.; RT "Functional and structural basis of carnitine palmitoyltransferase 1A RT deficiency."; RL J. Biol. Chem. 278:50428-50434(2003). RN [16] RP VARIANT CPT1AD ILE-314. RX PubMed=15669684; DOI=10.1023/b:boli.0000042979.42120.55; RA Stoler J.M., Sabry M.A., Hanley C., Hoppel C.L., Shih V.E.; RT "Successful long-term treatment of hepatic carnitine palmitoyltransferase I RT deficiency and a novel mutation."; RL J. Inherit. Metab. Dis. 27:679-684(2004). RN [17] RP VARIANTS CPT1AD GLY-316; VAL-343 AND TRP-465. RX PubMed=15110323; DOI=10.1016/j.ymgme.2004.02.004; RA Bennett M.J., Boriack R.L., Narayan S., Rutledge S.L., Raff M.L.; RT "Novel mutations in CPT 1A define molecular heterogeneity of hepatic RT carnitine palmitoyltransferase I deficiency."; RL Mol. Genet. Metab. 82:59-63(2004). CC -!- FUNCTION: Catalyzes the transfer of the acyl group of long-chain fatty CC acid-CoA conjugates onto carnitine, an essential step for the CC mitochondrial uptake of long-chain fatty acids and their subsequent CC beta-oxidation in the mitochondrion (PubMed:9691089, PubMed:11350182, CC PubMed:14517221, PubMed:16651524). Plays an important role in hepatic CC triglyceride metabolism (By similarity). {ECO:0000250|UniProtKB:P32198, CC ECO:0000269|PubMed:11350182, ECO:0000269|PubMed:14517221, CC ECO:0000269|PubMed:16651524, ECO:0000269|PubMed:9691089}. CC -!- CATALYTIC ACTIVITY: CC Reaction=(R)-carnitine + hexadecanoyl-CoA = CoA + O-hexadecanoyl-(R)- CC carnitine; Xref=Rhea:RHEA:12661, ChEBI:CHEBI:16347, CC ChEBI:CHEBI:17490, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379; EC=2.3.1.21; CC Evidence={ECO:0000269|PubMed:11350182, ECO:0000269|PubMed:14517221, CC ECO:0000269|PubMed:16651524, ECO:0000269|PubMed:9691089}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12662; CC Evidence={ECO:0000305|PubMed:11350182}; CC -!- ACTIVITY REGULATION: Inhibited by malonyl-CoA. CC {ECO:0000269|PubMed:14517221}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=89 uM for carnitine {ECO:0000269|PubMed:11350182}; CC KM=106.5 uM for carnitine {ECO:0000269|PubMed:14517221}; CC KM=43 uM for palmitoyl-CoA {ECO:0000269|PubMed:11350182}; CC KM=82.8 uM for palmitoyl-CoA {ECO:0000269|PubMed:14517221}; CC Vmax=15 nmol/min/mg enzyme toward carnitine CC {ECO:0000269|PubMed:11350182}; CC Vmax=147.8 nmol/min/mg enzyme toward carnitine CC {ECO:0000269|PubMed:14517221}; CC Vmax=40 nmol/min/mg enzyme toward palmitoyl-CoA CC {ECO:0000269|PubMed:11350182}; CC Vmax=88.6 nmol/min/mg enzyme toward palmitoyl-CoA CC {ECO:0000269|PubMed:14517221}; CC -!- PATHWAY: Lipid metabolism; fatty acid beta-oxidation. CC -!- SUBUNIT: Homohexamer and homotrimer (By similarity). Identified in a CC complex that contains at least CPT1A, ACSL1 and VDAC1 (By similarity). CC Also identified in complexes with ACSL1 and VDAC2 and VDAC3 (By CC similarity). {ECO:0000250|UniProtKB:P32198}. CC -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane CC {ECO:0000269|PubMed:11350182, ECO:0000269|PubMed:14517221}; Multi-pass CC membrane protein {ECO:0000255}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P50416-1; Sequence=Displayed; CC Name=2; CC IsoId=P50416-2; Sequence=VSP_012167; CC -!- TISSUE SPECIFICITY: Strong expression in kidney and heart, and lower in CC liver and skeletal muscle. CC -!- INDUCTION: Up-regulated by fatty acids. {ECO:0000269|PubMed:16271724}. CC -!- DOMAIN: A conformation change in the N-terminal region spanning the CC first 42 residues plays an important role in the regulation of enzyme CC activity by malonyl-CoA. {ECO:0000269|PubMed:21990363}. CC -!- DISEASE: Carnitine palmitoyltransferase 1A deficiency (CPT1AD) CC [MIM:255120]: Rare autosomal recessive metabolic disorder of long-chain CC fatty acid oxidation characterized by severe episodes of hypoketotic CC hypoglycemia usually occurring after fasting or illness. Onset is in CC infancy or early childhood. {ECO:0000269|PubMed:11350182, CC ECO:0000269|PubMed:11441142, ECO:0000269|PubMed:12111367, CC ECO:0000269|PubMed:12189492, ECO:0000269|PubMed:14517221, CC ECO:0000269|PubMed:15110323, ECO:0000269|PubMed:15669684, CC ECO:0000269|PubMed:9691089}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the carnitine/choline acetyltransferase family. CC {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L39211; AAC41748.1; -; mRNA. DR EMBL; AJ420747; CAD12625.1; -; Genomic_DNA. DR EMBL; AJ420748; CAD59673.1; -; Genomic_DNA. DR EMBL; BT009791; AAP88793.1; -; mRNA. DR EMBL; BC000185; AAH00185.1; -; mRNA. DR CCDS; CCDS31624.1; -. [P50416-2] DR CCDS; CCDS8185.1; -. [P50416-1] DR PIR; I59351; I59351. DR RefSeq; NP_001027017.1; NM_001031847.2. [P50416-2] DR RefSeq; NP_001867.2; NM_001876.3. [P50416-1] DR RefSeq; XP_016872709.1; XM_017017220.1. [P50416-1] DR PDB; 2LE3; NMR; -; A=1-42. DR PDBsum; 2LE3; -. DR AlphaFoldDB; P50416; -. DR BMRB; P50416; -. DR SMR; P50416; -. DR BioGRID; 107765; 191. DR IntAct; P50416; 50. DR MINT; P50416; -. DR STRING; 9606.ENSP00000265641; -. DR BindingDB; P50416; -. DR ChEMBL; CHEMBL1293194; -. DR DrugBank; DB01016; Glyburide. DR DrugBank; DB00583; Levocarnitine. DR DrugBank; DB01074; Perhexiline. DR DrugCentral; P50416; -. DR SwissLipids; SLP:000001056; -. DR TCDB; 4.C.2.1.3; the carnitine o-acyl transferase (carat) family. DR GlyGen; P50416; 3 sites, 1 O-linked glycan (3 sites). DR iPTMnet; P50416; -. DR MetOSite; P50416; -. DR PhosphoSitePlus; P50416; -. DR SwissPalm; P50416; -. DR BioMuta; CPT1A; -. DR DMDM; 56405343; -. DR EPD; P50416; -. DR jPOST; P50416; -. DR MassIVE; P50416; -. DR MaxQB; P50416; -. DR PaxDb; 9606-ENSP00000265641; -. DR PeptideAtlas; P50416; -. DR ProteomicsDB; 56220; -. [P50416-1] DR ProteomicsDB; 56221; -. [P50416-2] DR Pumba; P50416; -. DR Antibodypedia; 1640; 484 antibodies from 37 providers. DR DNASU; 1374; -. DR Ensembl; ENST00000265641.10; ENSP00000265641.4; ENSG00000110090.13. [P50416-1] DR Ensembl; ENST00000376618.6; ENSP00000365803.2; ENSG00000110090.13. [P50416-2] DR Ensembl; ENST00000539743.5; ENSP00000446108.1; ENSG00000110090.13. [P50416-1] DR Ensembl; ENST00000540367.5; ENSP00000439084.1; ENSG00000110090.13. [P50416-2] DR GeneID; 1374; -. DR KEGG; hsa:1374; -. DR MANE-Select; ENST00000265641.10; ENSP00000265641.4; NM_001876.4; NP_001867.2. DR UCSC; uc001oof.5; human. [P50416-1] DR AGR; HGNC:2328; -. DR CTD; 1374; -. DR DisGeNET; 1374; -. DR GeneCards; CPT1A; -. DR GeneReviews; CPT1A; -. DR HGNC; HGNC:2328; CPT1A. DR HPA; ENSG00000110090; Low tissue specificity. DR MalaCards; CPT1A; -. DR MIM; 255120; phenotype. DR MIM; 600528; gene. DR neXtProt; NX_P50416; -. DR OpenTargets; ENSG00000110090; -. DR Orphanet; 156; Carnitine palmitoyl transferase 1A deficiency. DR PharmGKB; PA26847; -. DR VEuPathDB; HostDB:ENSG00000110090; -. DR eggNOG; KOG3716; Eukaryota. DR GeneTree; ENSGT01060000248595; -. DR HOGENOM; CLU_013513_2_1_1; -. DR InParanoid; P50416; -. DR OMA; NTEHSWG; -. DR OrthoDB; 1429709at2759; -. DR PhylomeDB; P50416; -. DR TreeFam; TF313836; -. DR BioCyc; MetaCyc:HS03286-MONOMER; -. DR BRENDA; 2.3.1.21; 2681. DR PathwayCommons; P50416; -. DR Reactome; R-HSA-1368082; RORA activates gene expression. DR Reactome; R-HSA-1989781; PPARA activates gene expression. DR Reactome; R-HSA-200425; Carnitine metabolism. DR Reactome; R-HSA-5362517; Signaling by Retinoic Acid. DR SABIO-RK; P50416; -. DR SignaLink; P50416; -. DR SIGNOR; P50416; -. DR UniPathway; UPA00659; -. DR BioGRID-ORCS; 1374; 14 hits in 1172 CRISPR screens. DR ChiTaRS; CPT1A; human. DR GenomeRNAi; 1374; -. DR Pharos; P50416; Tchem. DR PRO; PR:P50416; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; P50416; Protein. DR Bgee; ENSG00000110090; Expressed in jejunal mucosa and 199 other cell types or tissues. DR ExpressionAtlas; P50416; baseline and differential. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IMP:UniProtKB. DR GO; GO:0005739; C:mitochondrion; IDA:HPA. DR GO; GO:0004095; F:carnitine O-palmitoyltransferase activity; IDA:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:1990698; F:palmitoleoyltransferase activity; IEA:Ensembl. DR GO; GO:0046222; P:aflatoxin metabolic process; IEA:Ensembl. DR GO; GO:0009437; P:carnitine metabolic process; IDA:UniProtKB. DR GO; GO:0006853; P:carnitine shuttle; TAS:Reactome. DR GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl. DR GO; GO:0042755; P:eating behavior; IEA:Ensembl. DR GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProtKB. DR GO; GO:0006635; P:fatty acid beta-oxidation; TAS:ProtInc. DR GO; GO:0006631; P:fatty acid metabolic process; IBA:GO_Central. DR GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl. DR GO; GO:0097421; P:liver regeneration; IEA:Ensembl. DR GO; GO:0001676; P:long-chain fatty acid metabolic process; IDA:UniProtKB. DR GO; GO:0032000; P:positive regulation of fatty acid beta-oxidation; IEA:Ensembl. DR GO; GO:0050796; P:regulation of insulin secretion; IEA:Ensembl. DR GO; GO:0010883; P:regulation of lipid storage; IEA:Ensembl. DR GO; GO:0043279; P:response to alkaloid; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0001666; P:response to hypoxia; IEA:Ensembl. DR GO; GO:0007584; P:response to nutrient; IEA:Ensembl. DR GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl. DR GO; GO:1904772; P:response to tetrachloromethane; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl. DR Gene3D; 6.10.250.1760; -; 1. DR Gene3D; 3.30.559.10; Chloramphenicol acetyltransferase-like domain; 1. DR Gene3D; 3.30.559.70; Choline/Carnitine o-acyltransferase, domain 2; 1. DR InterPro; IPR000542; Carn_acyl_trans. DR InterPro; IPR023213; CAT-like_dom_sf. DR InterPro; IPR039551; Cho/carn_acyl_trans. DR InterPro; IPR042231; Cho/carn_acyl_trans_2. DR InterPro; IPR032476; CPT_N. DR PANTHER; PTHR22589; CARNITINE O-ACYLTRANSFERASE; 1. DR PANTHER; PTHR22589:SF74; CARNITINE O-PALMITOYLTRANSFERASE 1, LIVER ISOFORM; 1. DR Pfam; PF00755; Carn_acyltransf; 1. DR Pfam; PF16484; CPT_N; 1. DR SUPFAM; SSF52777; CoA-dependent acyltransferases; 2. DR PROSITE; PS00439; ACYLTRANSF_C_1; 1. DR PROSITE; PS00440; ACYLTRANSF_C_2; 1. DR Genevisible; P50416; HS. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Acyltransferase; Alternative splicing; KW Disease variant; Fatty acid metabolism; Lipid metabolism; Membrane; KW Mitochondrion; Mitochondrion outer membrane; Nitration; Phosphoprotein; KW Reference proteome; Transferase; Transmembrane; Transmembrane helix; KW Transport. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P32198" FT CHAIN 2..773 FT /note="Carnitine O-palmitoyltransferase 1, liver isoform" FT /id="PRO_0000210159" FT TOPO_DOM 2..47 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 48..73 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 74..102 FT /note="Mitochondrial intermembrane" FT /evidence="ECO:0000255" FT TRANSMEM 103..122 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 123..773 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT ACT_SITE 473 FT /note="Proton acceptor" FT /evidence="ECO:0000250|UniProtKB:P18886" FT BINDING 555..567 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250|UniProtKB:P18886" FT BINDING 589 FT /ligand="(R)-carnitine" FT /ligand_id="ChEBI:CHEBI:16347" FT /evidence="ECO:0000250|UniProtKB:P18886" FT BINDING 602 FT /ligand="(R)-carnitine" FT /ligand_id="ChEBI:CHEBI:16347" FT /evidence="ECO:0000250|UniProtKB:P18886" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000250|UniProtKB:P32198" FT MOD_RES 282 FT /note="3'-nitrotyrosine" FT /evidence="ECO:0000250|UniProtKB:P32198" FT MOD_RES 588 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P32198" FT MOD_RES 589 FT /note="3'-nitrotyrosine" FT /evidence="ECO:0000250|UniProtKB:P32198" FT MOD_RES 604 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P32198" FT MOD_RES 741 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P32198" FT MOD_RES 747 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P32198" FT VAR_SEQ 746..773 FT /note="DSHRFGRHLKEAMTDIITLFGLSSNSKK -> GIISQGPSSDT (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.3" FT /id="VSP_012167" FT VARIANT 123 FT /note="R -> C (in CPT1AD; dbSNP:rs80356775)" FT /evidence="ECO:0000269|PubMed:11441142" FT /id="VAR_020546" FT VARIANT 275 FT /note="A -> T (in dbSNP:rs2229738)" FT /evidence="ECO:0000269|PubMed:11441142, FT ECO:0000269|PubMed:12189492, ECO:0000269|PubMed:14517221" FT /id="VAR_020547" FT VARIANT 304 FT /note="C -> W (in CPT1AD; dbSNP:rs80356789)" FT /evidence="ECO:0000269|PubMed:11441142" FT /id="VAR_020548" FT VARIANT 314 FT /note="T -> I (in CPT1AD; dbSNP:rs80356776)" FT /evidence="ECO:0000269|PubMed:15669684" FT /id="VAR_020549" FT VARIANT 316 FT /note="R -> G (in CPT1AD; dbSNP:rs80356796)" FT /evidence="ECO:0000269|PubMed:15110323" FT /id="VAR_046767" FT VARIANT 343 FT /note="F -> V (in CPT1AD; dbSNP:rs80356783)" FT /evidence="ECO:0000269|PubMed:15110323" FT /id="VAR_046768" FT VARIANT 357 FT /note="R -> W (in CPT1AD; decreased stability; FT dbSNP:rs80356777)" FT /evidence="ECO:0000269|PubMed:11441142" FT /id="VAR_020550" FT VARIANT 360 FT /note="E -> G (in CPT1AD; reduced protein levels; FT dbSNP:rs80356787)" FT /evidence="ECO:0000269|PubMed:12111367" FT /id="VAR_020551" FT VARIANT 395 FT /note="Missing (in CPT1AD; loss of activity)" FT /evidence="ECO:0000269|PubMed:11441142" FT /id="VAR_020552" FT VARIANT 414 FT /note="A -> V (in CPT1AD; decreased activity; FT dbSNP:rs80356790)" FT /evidence="ECO:0000269|PubMed:12189492, FT ECO:0000269|PubMed:14517221" FT /id="VAR_020553" FT VARIANT 454 FT /note="D -> G (in CPT1AD; loss of activity; FT dbSNP:rs80356778)" FT /evidence="ECO:0000269|PubMed:9691089" FT /id="VAR_020554" FT VARIANT 465 FT /note="G -> W (in CPT1AD; dbSNP:rs80356784)" FT /evidence="ECO:0000269|PubMed:15110323" FT /id="VAR_046769" FT VARIANT 479 FT /note="P -> L (in CPT1AD; decreased activity; FT dbSNP:rs80356779)" FT /evidence="ECO:0000269|PubMed:11441142" FT /id="VAR_020555" FT VARIANT 484 FT /note="L -> P (in CPT1AD; dbSNP:rs80356793)" FT /evidence="ECO:0000269|PubMed:11441142" FT /id="VAR_020556" FT VARIANT 498 FT /note="Y -> C (in CPT1AD; decreased activity; FT dbSNP:rs80356791)" FT /evidence="ECO:0000269|PubMed:12189492, FT ECO:0000269|PubMed:14517221" FT /id="VAR_020557" FT VARIANT 709 FT /note="G -> E (in CPT1AD; loss of activity; FT dbSNP:rs28936374)" FT /evidence="ECO:0000269|PubMed:14517221" FT /id="VAR_020558" FT VARIANT 710 FT /note="G -> E (in CPT1AD; loss of activity; FT dbSNP:rs80356780)" FT /evidence="ECO:0000269|PubMed:11350182, FT ECO:0000269|PubMed:14517221" FT /id="VAR_020559" FT MUTAGEN 473 FT /note="H->A: Loss of carnitine O-palmitoyltransferase FT activity." FT /evidence="ECO:0000269|PubMed:16651524" FT CONFLICT 479 FT /note="P -> Q (in Ref. 1; AAC41748)" FT /evidence="ECO:0000305" FT CONFLICT 568 FT /note="A -> T (in Ref. 1; AAC41748)" FT /evidence="ECO:0000305" FT HELIX 4..7 FT /evidence="ECO:0007829|PDB:2LE3" FT STRAND 9..15 FT /evidence="ECO:0007829|PDB:2LE3" FT STRAND 18..23 FT /evidence="ECO:0007829|PDB:2LE3" FT HELIX 25..39 FT /evidence="ECO:0007829|PDB:2LE3" SQ SEQUENCE 773 AA; 88368 MW; E5DC9141B6301947 CRC64; MAEAHQAVAF QFTVTPDGID LRLSHEALRQ IYLSGLHSWK KKFIRFKNGI ITGVYPASPS SWLIVVVGVM TTMYAKIDPS LGIIAKINRT LETANCMSSQ TKNVVSGVLF GTGLWVALIV TMRYSLKVLL SYHGWMFTEH GKMSRATKIW MGMVKIFSGR KPMLYSFQTS LPRLPVPAVK DTVNRYLQSV RPLMKEEDFK RMTALAQDFA VGLGPRLQWY LKLKSWWATN YVSDWWEEYI YLRGRGPLMV NSNYYAMDLL YILPTHIQAA RAGNAIHAIL LYRRKLDREE IKPIRLLGST IPLCSAQWER MFNTSRIPGE ETDTIQHMRD SKHIVVYHRG RYFKVWLYHD GRLLKPREME QQMQRILDNT SEPQPGEARL AALTAGDRVP WARCRQAYFG RGKNKQSLDA VEKAAFFVTL DETEEGYRSE DPDTSMDSYA KSLLHGRCYD RWFDKSFTFV VFKNGKMGLN AEHSWADAPI VAHLWEYVMS IDSLQLGYAE DGHCKGDINP NIPYPTRLQW DIPGECQEVI ETSLNTANLL ANDVDFHSFP FVAFGKGIIK KCRTSPDAFV QLALQLAHYK DMGKFCLTYE ASMTRLFREG RTETVRSCTT ESCDFVRAMV DPAQTVEQRL KLFKLASEKH QHMYRLAMTG SGIDRHLFCL YVVSKYLAVE SPFLKEVLSE PWRLSTSQTP QQQVELFDLE NNPEYVSSGG GFGPVADDGY GVSYILVGEN LINFHISSKF SCPETDSHRF GRHLKEAMTD IITLFGLSSN SKK //